MA54657A - Compositions pour augmenter la demi-vie d'un agent thérapeutique chez les chiens et procédés d'utilisation - Google Patents

Compositions pour augmenter la demi-vie d'un agent thérapeutique chez les chiens et procédés d'utilisation

Info

Publication number
MA54657A
MA54657A MA054657A MA54657A MA54657A MA 54657 A MA54657 A MA 54657A MA 054657 A MA054657 A MA 054657A MA 54657 A MA54657 A MA 54657A MA 54657 A MA54657 A MA 54657A
Authority
MA
Morocco
Prior art keywords
dogs
compositions
life
increasing
methods
Prior art date
Application number
MA054657A
Other languages
English (en)
Inventor
William Brondyk
Brett Chevalier
Juergen Horn
Madhusudan Natarajan
Original Assignee
Invetx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invetx Inc filed Critical Invetx Inc
Publication of MA54657A publication Critical patent/MA54657A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA054657A 2019-01-03 2020-01-02 Compositions pour augmenter la demi-vie d'un agent thérapeutique chez les chiens et procédés d'utilisation MA54657A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962788035P 2019-01-03 2019-01-03

Publications (1)

Publication Number Publication Date
MA54657A true MA54657A (fr) 2021-11-10

Family

ID=69740520

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054657A MA54657A (fr) 2019-01-03 2020-01-02 Compositions pour augmenter la demi-vie d'un agent thérapeutique chez les chiens et procédés d'utilisation

Country Status (9)

Country Link
US (7) US11542333B2 (fr)
EP (1) EP3906259A2 (fr)
CN (2) CN120005022A (fr)
AU (1) AU2020205073B2 (fr)
BR (1) BR112021012513A2 (fr)
MA (1) MA54657A (fr)
MX (1) MX2021008144A (fr)
SG (1) SG11202106478UA (fr)
WO (1) WO2020142625A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
AU2018318440A1 (en) 2017-08-15 2020-02-13 Kindred Biosciences, Inc. IgG Fc variants for veterinary use
WO2020116560A1 (fr) * 2018-12-05 2020-06-11 株式会社バイカ・セラピュティクス Produit modifié de domaine fc d'anticorps
CN120005022A (zh) 2019-01-03 2025-05-16 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
JP7671275B2 (ja) 2019-08-29 2025-05-01 エランコ・ユーエス・インコーポレイテッド 動物用の抗ｉｌ３１抗体
CN115135669B (zh) 2020-02-19 2026-05-19 硕腾服务有限责任公司 修饰的Fc区
IL297287A (en) * 2020-04-17 2022-12-01 Zoetis Services Llc Canine antibody variants
CA3173864A1 (fr) * 2020-04-22 2021-10-28 Shyr Jiann Li Anticorps anti-il31 a action prolongee a usage veterinaire
GB202005879D0 (en) * 2020-04-22 2020-06-03 Petmedix Ltd Heterodimeric proteins
JP7832123B2 (ja) 2020-05-11 2026-03-17 インベテックス インコーポレイテッド 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法
EP4166574A4 (fr) * 2020-06-10 2025-01-15 Bica Therapeutics Inc. Protéine de fusion contenant un polypeptide d'érythropoïétine
CN116096741B (zh) 2020-07-10 2024-10-18 因外泰克斯公司 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法
CA3194936A1 (fr) * 2020-09-28 2022-03-31 Zoetis Services Llc Variants d'anticorps canin
EP4255933A4 (fr) * 2020-12-07 2025-07-23 Invetx Inc Compositions permettant d'augmenter la demi-vie d'un agent thérapeutique chez des animaux d'élevage et procédés d'utilisation
MX2023008785A (es) * 2021-01-28 2023-12-14 Zoetis Services Llc Mutaciones en regiones constantes de anticuerpos caninos.
EP4380974A1 (fr) * 2021-08-06 2024-06-12 Petmedix Ltd. Variants de fc d'anticorps
WO2023021169A1 (fr) * 2021-08-20 2023-02-23 Intervet International B.V. Anticorps et protéines de fusion igg présentant une demi-vie accrue
US11608371B1 (en) * 2021-10-21 2023-03-21 Petmedix Ltd Therapeutic molecules
MX2024004875A (es) 2021-10-21 2024-07-19 Petmedix Ltd Proteinas que comprenden en el dominio extracelular de p75ntr.
AU2022409610A1 (en) * 2021-12-16 2024-05-30 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha 1
CN120603608A (zh) * 2022-12-16 2025-09-05 维特玛博生物科学公司 抗IL23和抗TNFα抗体：组合物和兽医用途
KR20250137204A (ko) 2022-12-27 2025-09-17 인베티엑스 인코포레이티드 신생아 fc 수용체(fcrn)에 대한 결합이 변경된 폴리펩타이드 및 사용 방법
US20240254231A1 (en) 2023-01-20 2024-08-01 PetMedix Ltd. Therapeutic antibodies
CN121002059A (zh) 2023-01-20 2025-11-21 因外泰克斯公司 用于伴侣动物的双特异性结合剂
CN120712277A (zh) 2023-02-09 2025-09-26 佩特迈迪有限公司 包含p75神经营养因子受体(p75ntr)胞外结构域变体的治疗分子
CN120897928A (zh) * 2023-02-13 2025-11-04 英特维特国际股份有限公司 针对犬il-4的犬抗体
US20260234236A1 (en) * 2023-02-13 2026-08-13 Intervet Inc. Canine antibodies to canine il-13
WO2026125320A1 (fr) 2024-12-10 2026-06-18 Intervet International B.V. Anticorps il31ralpha caninisés ayant une demi-vie prolongée
WO2026125321A1 (fr) 2024-12-10 2026-06-18 Intervet International B.V. Anticorps anti-il31rα caninisés ayant une demi-vie prolongée
WO2026125322A1 (fr) 2024-12-10 2026-06-18 Intervet International B.V. ANTICORPS ANTI-IL31Rα CANINISÉS AYANT UNE DEMI-VIE PROLONGÉE

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
DK0575319T3 (da) 1991-03-11 2000-07-10 Univ Georgia Res Found Kloning og ekspression af Renilla-luciferase
CA2169298A1 (fr) 1993-09-10 1995-03-16 Martin Chalfie Utilisations d'une proteine fluorescente verte
WO1995021191A1 (fr) 1994-02-04 1995-08-10 William Ward Indicateur bioluminescent fonde sur l'expression d'un gene codant pour une proteine modifiee a fluorescence verte
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
ATE290205T1 (de) 1996-12-12 2005-03-15 Prolume Ltd Vorrichtung und verfahren zum nachweis und identifizieren von infektiösen wirkstoffen
AU765703B2 (en) 1998-03-27 2003-09-25 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
WO2005047327A2 (fr) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
CA2577133A1 (fr) 2004-08-19 2006-03-23 Genentech, Inc. Variants de polypeptides dotes d'une fonction effectrice modifiee
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2010110838A2 (fr) * 2009-03-25 2010-09-30 Vet Therapeutics Inc. Régions de domaine constant d'anticorps et leurs utilisations
CA2754408A1 (fr) * 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Proteines hybrides comprenant des portions fc d'anticorps canins
WO2010117448A2 (fr) 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Immunocytokines chimériques et leurs procédés d'utilisation
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20130129727A1 (en) 2011-11-17 2013-05-23 Nanjingjinsirui Science & Technology Biology Corporation Methods and systems for increasing protein stability
MX360368B (es) * 2012-04-27 2018-10-29 Bioatla Llc Regiones de anticuerpo modificado y sus usos.
CN114773469B (zh) * 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
FI3284480T3 (fi) * 2015-04-14 2025-09-11 Chugai Pharmaceutical Co Ltd IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi
US11596699B2 (en) * 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
EP3481413A4 (fr) 2016-07-08 2020-01-08 Askgene Pharma, Inc. Protéine de fusion comprenant de la leptine et procédés de production et d'utilisation associés
EP3526246A1 (fr) * 2016-10-17 2019-08-21 Vetoquinol SA Région constante modifiée d'un anticorps
AU2018318440A1 (en) 2017-08-15 2020-02-13 Kindred Biosciences, Inc. IgG Fc variants for veterinary use
BR112020017701A2 (pt) 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
JP2022500037A (ja) 2018-09-14 2022-01-04 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のための抗ｉｌ４受容体抗体
EP3866842A4 (fr) 2018-10-18 2022-07-13 Kindred Biosciences, Inc. Variants fc présentant une liaison modifiée au récepteur fc néonatal (fcrn) à usage vétérinaire
WO2020116560A1 (fr) 2018-12-05 2020-06-11 株式会社バイカ・セラピュティクス Produit modifié de domaine fc d'anticorps
WO2020139984A1 (fr) 2018-12-27 2020-07-02 Kindred Biosciences, Inc. Variants d'igg fc à usage vétérinaire
CN120005022A (zh) 2019-01-03 2025-05-16 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
CN115135669B (zh) 2020-02-19 2026-05-19 硕腾服务有限责任公司 修饰的Fc区
IL297287A (en) 2020-04-17 2022-12-01 Zoetis Services Llc Canine antibody variants
EP4136109A1 (fr) 2020-04-17 2023-02-22 Zoetis Services LLC Variants d'anticorps félin
JP7832123B2 (ja) 2020-05-11 2026-03-17 インベテックス インコーポレイテッド 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法
CN116096741B (zh) 2020-07-10 2024-10-18 因外泰克斯公司 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法

Also Published As

Publication number Publication date
US11548949B2 (en) 2023-01-10
AU2020205073A1 (en) 2021-08-19
CN113544153B (zh) 2024-12-10
AU2020205073B2 (en) 2026-05-28
US11542333B2 (en) 2023-01-03
US20200362035A1 (en) 2020-11-19
EP3906259A2 (fr) 2021-11-10
US20230279118A1 (en) 2023-09-07
CN120005022A (zh) 2025-05-16
SG11202106478UA (en) 2021-07-29
US20240239896A1 (en) 2024-07-18
WO2020142625A3 (fr) 2020-10-08
CN113544153A (zh) 2021-10-22
US20240166748A1 (en) 2024-05-23
WO2020142625A2 (fr) 2020-07-09
WO2020142625A4 (fr) 2020-12-10
MX2021008144A (es) 2021-10-13
US20200216536A1 (en) 2020-07-09
BR112021012513A2 (pt) 2021-09-14
WO2020142625A9 (fr) 2021-06-24
US20240166749A1 (en) 2024-05-23
US20240239897A1 (en) 2024-07-18

Similar Documents

Publication Publication Date Title
EP3982932A4 (fr) Compositions et procédés pour véhicules d'administration biologiques
EP3820885A4 (fr) Procédés et compositions pour l'administration d'agents à travers la barrière hémato-encéphalique
EP3874030A4 (fr) Compositions et procédés pour l'ingénierie des lymphocytes t
EP3840730A4 (fr) Compositions pour l'administration d'agents thérapeutiques et leurs méthodes d'utilisation et leurs procédés de préparation
EP4037695A4 (fr) Compositions oligonucléotidiques et leurs procédés d'utilisation
EP3958872A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3790596A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3911338A4 (fr) Compositions et procédés d'inhibition d'antigènes spécifiques de lignée
EP3898942A4 (fr) Compositions de nanoparticules pour l'administration efficace d'acides nucléiques et leurs procédés de fabrication et d'utilisation
SG11202106478UA (en) Compositions for increasing half-life of a therapeutic agent in canines and methods of use
MA51766A (fr) Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
MA53015A (fr) Anticorps anti-sirp-bêta1 et procédés d'utilisation associés
MA56455A (fr) Auto-injecteur et procédés d'utilisation associés
EP3774892A4 (fr) Anticorps dirigés contre un composant du complément et procédés d'utilisation
EP3953385A4 (fr) Anticorps cd19 et leurs procédés d'utilisation
EP3826468A4 (fr) Compositions pour l'agriculture et procédés associés
EP3877527A4 (fr) Compositions et procédés pour le criblage in vivo d'agents thérapeutiques
EP3803403A4 (fr) Compositions et procédés d'imagerie
EP3781683A4 (fr) Procédés et compositions pour l'édition génomique
EP3917543A4 (fr) Compositions de nitrate améliorées et procédés d'utilisation
MA53167A (fr) Récepteurs chimériques de steap1 et procédés d'utilisation associées
EP4017543A4 (fr) Compositions et procédés pour l'édition de gènes in vivo
MA51453A (fr) Conjugués anticorps anti-sez6-médicaments et procédés d'utilisation
EP3938400A4 (fr) Anticorps cd22 et leurs procédés d'utilisation
EP4048402A4 (fr) Lymphocytes t cytoxiques modifiés et leurs procédés d'utilisation